This bill amends R.S. 22:1076.1 to revise the composition and operational procedures of the advisory board for rare cancer treatments in Louisiana. The board will now consist of seventeen members, including representatives from various health departments and organizations, with a notable change being the replacement of the executive director of "Taking Aim at Cancer in Louisiana" with the executive director of the "Cancer Association of Louisiana." Additionally, the number of oncologists specializing in rare cancers has increased from two to four.

The bill also stipulates that the advisory board will hold quarterly public meetings and must compile and submit a formal report of its findings to the House Committee on Insurance and the Senate Committee on Insurance no later than forty-five days after each meeting. The commissioner is granted the authority to adopt necessary administrative rules to implement these provisions. The act will take effect upon the governor's signature or after the designated period for bills to become law without signature.

Statutes affected:
HB761 Original:
HB761 Engrossed:
HB761 Reengrossed:
HB761 Enrolled:
HB761 Act 832: